AEMD - Aethlon Medical, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
1.1301
-0.0199 (-1.73%)
As of 1:22PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close1.1500
Open1.1600
Bid1.1300 x 1100
Ask1.1500 x 900
Day's Range1.1300 - 1.1600
52 Week Range0.7900 - 3.8500
Volume8,125
Avg. Volume95,298
Market Cap20.072M
Beta2.00
PE Ratio (TTM)N/A
EPS (TTM)-0.4610
Earnings DateOct 31, 2018 - Nov 5, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Trade prices are not sourced from all markets
  • PR Newswire6 days ago

    Aethlon Medical Announces First Quarter Fiscal Year 2019 Results

    SAN DIEGO , Aug. 8, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced results for its fiscal ...

  • ACCESSWIRE6 days ago

    Aethlon Medical, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Aethlon Medical, Inc. (NASDAQ: AEMD ) will be discussing their earnings results in their Q1 Earnings Call to be held on August 8, 2018 at 4:30 PM Eastern Time. ...

  • PR Newswire12 days ago

    Aethlon Medical To Release Financial Results for the First Quarter Fiscal Year 2019 and Host Conference Call on August 8, 2018

    SAN DIEGO , Aug. 2, 2018  /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense today announced it will issue financial ...

  • Loss-Making Aethlon Medical Inc (NASDAQ:AEMD) Expected To Breakeven
    Simply Wall St.2 months ago

    Loss-Making Aethlon Medical Inc (NASDAQ:AEMD) Expected To Breakeven

    Aethlon Medical Inc’s (NASDAQ:AEMD): Aethlon Medical, Inc., a medical device company, focuses on creating devices that address unmet medical needs in health and biodefense worldwide. On 31 March 2018, theRead More...

  • PR Newswire2 months ago

    Guy Cipriani Joins Aethlon Medical's Board of Directors

    SAN DIEGO, June 25, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced the appointment of Guy Cipriani to its Board of Directors. Mr. Cipriani qualifies as an independent director under the Nasdaq Rules. Mr. Cipriani is a business executive with nearly 20 years of experience in the pharmaceutical and biotech industries.

  • GlobeNewswire2 months ago

    New Research: Key Drivers of Growth for Nicolet Bankshares, Vitamin Shoppe, Aethlon Medical, Barrett Business Services, Veracyte, and TPG Specialty Lending — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, June 21, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Nicolet ...

  • Zacks Small Cap Research2 months ago

    AEMD: AEMD In Active Discussions With FDA Regarding Hemopurifier Pathway

    Revenue of $75k, which was largely inline with our $89k estimate, relates entirely to a second milestone from the NCI cancer grant. Subsequent to the close of fiscal 2018, AEMD billed an additional $112k for work completed under this grant.

  • PR Newswire2 months ago

    Aethlon Medical Announces Fiscal 2018 Results

    SAN DIEGO , June 8, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced results for its fiscal ...

  • PR Newswire2 months ago

    Aethlon Medical To Release 2018 Fiscal Year End Financial Results and Host Conference Call on June 8, 2018

    Also Presenting at 2018 BIO International Convention on June 6, 2018 SAN DIEGO , May 31, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs ...

  • Are Aethlon Medical Inc’s (NASDAQ:AEMD) Interest Costs Too High?
    Simply Wall St.3 months ago

    Are Aethlon Medical Inc’s (NASDAQ:AEMD) Interest Costs Too High?

    Aethlon Medical Inc (NASDAQ:AEMD) is a small-cap stock with a market capitalization of US$21.04M. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, theyRead More...

  • ACCESSWIRE4 months ago

    GVC Capital and Trickle Research Announce Presenter Schedule for Rocky Mountain MicroCap Conference II in Denver on April 24, 2018

    DENVER, CO / ACCESSWIRE / April 20, 2018 / GVC Capital LLC ("GVC") and Dave Lavigne at Trickle Research LLC ("Trickle Research") will host the Rocky Mountain MicroCap Conference II ...

  • PR Newswire5 months ago

    Study of Blood Test to Detect and Monitor Chronic Traumatic Encephalopathy (CTE) in Former NFL Players Set for Kick-Off in Phoenix

    PHOENIX and SAN DIEGO, March 22, 2018 /PRNewswire/ -- Exosome Sciences, Inc., a diagnostic subsidiary of Aethlon Medical, Inc. (AEMD), today announced the initiation of an Institutional Review Board (IRB) approved protocol for a research study involving retired NFL players and a data-supported biomarker candidate to potentially detect and monitor Chronic Traumatic Encephalopathy (CTE) in living individuals. The sample collection will be conducted in collaboration with Kendall Van Keuren-Jensen, Ph.D., co-director of the Translational Genomics Research Institute's (TGen) Center for Noninvasive Diagnostics, for biomarker discovery projects. With the approval of the protocol, investigators plan to initiate screening of candidate participants in the coming weeks.  The study will enroll former NFL players, who are at high-risk of suffering from CTE, and control subjects who didn't participate in activities that involved repetitive head trauma.

  • PR Newswire6 months ago

    Aethlon Medical To Present at the American Society for Microbiology Biothreats Meeting

    SAN DIEGO, Feb. 12, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, announced today that its CEO, Jim Joyce will give a presentation at the 2018 American Society for Microbiology (ASM) Biothreats Meeting.  The presentation entitled: "A Broad-Spectrum Platform to Address Life-Threating Viral Infections," is scheduled to begin at 8:30am eastern on February 14th.  The presentation slide-deck will be made available on the Aethlon Medical website at https://www.aethlonmedical.com/news-media/presentations. The American Society for Microbiology Biothreats Meeting is being held today, February 12th through the 14th at the Hilton, Baltimore Md.  The event includes tracks on high consequence pathogen research, biological threat reduction, product development, and policy.

  • Zacks Small Cap Research6 months ago

    AEMD: Q3 Results. Hemopurifier Pathway Could Benefit From New FDA Mindset

    By Brian Marckx, CFA NASDAQ:AEMD Fiscal Q3 2018 Financials, Operational Update Aethlon Medical (NASDAQ:AEMD) reported financial results for their fiscal third quarter 2018 ending December 31st and provided ...

  • PR Newswire6 months ago

    Aethlon Medical Announces Fiscal 2018 Third Quarter Results

    SAN DIEGO , Feb. 1, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced results for its fiscal ...

  • PR Newswire6 months ago

    Aethlon Medical to Release Third Quarter Fiscal Year 2018 Financial Results and Host Conference Call on February 1, 2018

    SAN DIEGO , Jan. 29, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense today announced it will issue third ...

  • PR Newswire7 months ago

    Aethlon Medical Announces Validation Completion for European Patent Protecting Methods of Quantifying Exosomes

    SAN DIEGO, Jan. 23, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, announced today that validation has completed and the opposition period expired for European Patent Number 2591359, entitled "METHODS AND COMPOSITIONS FOR QUANTIFYING EXOSOMES." The patent was validated in Germany, France, Great Britain, and Spain. In recent years, exosomes have emerged as a significant diagnostic and therapeutic tool for a wide range of disease conditions, including cancer, tuberculosis, Alzheimer's, and chronic traumatic encephalopathy (CTE).

  • Is It The Right Time To Buy Aethlon Medical Inc (NASDAQ:AEMD)?
    Simply Wall St.7 months ago

    Is It The Right Time To Buy Aethlon Medical Inc (NASDAQ:AEMD)?

    Aethlon Medical Inc (NASDAQ:AEMD), a medical equipment company based in United States, led the NasdaqCM gainers with a relatively large price hike in the past couple of weeks. Less-covered, smallRead More...

  • PR Newswire7 months ago

    Aethlon Medical Announces Allowance of U.S. Patent that Broadens Protection for the Aethlon Hemopurifier® to Treat Viral Infections

    SAN DIEGO, Jan. 18, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced that the United States Patent and Trademark Office has allowed U.S. Patent Application Number 14/490,418 ("the '418 Application"), entitled "METHOD FOR REMOVAL OF VIRUSES FROM BLOOD BY LECTIN AFFINITY HEMODIALYSIS." The allowed claims of the '418 Application embody cartridges for the Aethlon Hemopurifier®, which removes viral particles from the blood or plasma of infected patients.  The '418 Application is a continuation of U.S. Patent Number 7,226,429, which embodies methods of reducing viral loads in the blood of individuals infected with a virus. Together, this intellectual property further protects the Aethlon Hemopurifier® and secures Aethlon's position as a leader in pioneering therapeutic strategies to address viral infections.

  • PR Newswire7 months ago

    Sabrina Martucci Johnson Joins Aethlon Medical's Board of Directors

    SAN DIEGO, Jan. 10, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced the appointment of Sabrina Martucci Johnson to its Board of Directors and to its Audit Committee. "We are very pleased to have Sabrina join the Aethlon team," stated Aethlon Medical founder and CEO, Jim Joyce.

  • Benzinga7 months ago

    Aethlon Shares Jump Before '60 Minutes' Report On CTE, Vets

    Aethlon Medical (NASDAQ: AEMD ) reportedly plays a part in a “60 Minutes” segment on CTE in combat veterans that’s airing Sunday. The story says combat veterans exposed to bomb blasts are being diagnosed ...

  • How Does Aethlon Medical Inc’s (NASDAQ:AEMD) Earnings Growth Stack Up Against Industry Performance?
    Simply Wall St.8 months ago

    How Does Aethlon Medical Inc’s (NASDAQ:AEMD) Earnings Growth Stack Up Against Industry Performance?

    When Aethlon Medical Inc (NASDAQ:AEMD) announced its most recent earnings (30 September 2017), I compared it against two factor: its historical earnings track record, and the performance of its industryRead More...